The NIH Grant money and CHA U, KSC and Dongyang Corp paid the bills. Well NIH hopefully will be excited about a Grant {paying off}?.
This work was supported by National Institutes of
Health (NIH) grants MH48866 and DC 006501 and
by International Grants from the CHA University,
Korean Stem Cell Research Center, and Dongyang
Corporation Co. in Korea. The authors thank Dr. V.
Morgan (Harvard Partners Center for Genetics and
Genomics), Dr. J. Kim (Harvard Medical School),
andDr. J. Lee (ShippensburgUniversity) formicroarray
analysis and Ms. J. Johnson (Cell Line Genetics)
for karyotyping analysis. R.L. is an employee and
shareholder of Advanced Cell Technology and
a scientific advisor for Stem Cell and Regenerative
Medicine International. K.Y.C. is a shareholder of
CHA Bio and Diostech Co., Ltd., and Stem Cell
and Regenerative Medicine International.
In conclusion,
the system described here eliminates the
potential risks associated with chromosomal
chromosomal
integrations and/or mutations and
may allow the translation of hiPSC technology
into the clinic.
